Oncotelic and Sapu Bioscience Define Sub-15 nm Nanoparticles as New Frontier in Drug Delivery
Oncotelic Therapeutics and Sapu Bioscience have published a landmark review establishing sub-15 nm nanoparticles as a breakthrough drug delivery platform capable of overcoming limitations of current therapies through enhanced tissue penetration and reduced toxicity.
A comprehensive review published by Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and joint venture partner Sapu Bioscience establishes sub-15 nm nanoparticles as an emerging frontier in drug delivery with significant therapeutic potential. The paper, titled "Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential," appears in the International Journal of Molecular Sciences (IJMS 2025, 26, 10842; https://doi.org/10.3390/ijms262210842) and represents the first systematic examination of nanoparticles exclusively within the 5–15 nm range.
Authored by Dr. Tapas De, Vuong Trieu, Scott Myers, Sanjive Qazi, Saran Saund, and Cynthia Lee, the review demonstrates how these sub-15 nm systems achieve superior performance characteristics compared to both small molecules and larger nanocarriers. The research highlights their ability to penetrate tissues more deeply, accumulate less in organs, clear faster through renal pathways, and diffuse more effectively across biological barriers including the blood-brain barrier.
This breakthrough size regime establishes a new pharmacological paradigm that could overcome the delivery and toxicity limitations that have hampered both conventional small molecule drugs and larger nanoparticle carriers. The enhanced diffusion capabilities of sub-15 nm nanoparticles make them particularly promising for treating conditions where biological barriers have traditionally limited therapeutic effectiveness.
The publication marks a significant milestone in nanomedicine development, positioning sub-15 nm nanoparticles as a transformative technology for drug delivery applications. The comprehensive analysis provides researchers and pharmaceutical developers with critical insights into how this specific size range offers unique advantages for therapeutic applications across multiple disease areas.
Oncotelic Therapeutics, as a clinical-stage biopharmaceutical company focused on oncology and immunotherapy products, stands to benefit from these developments through its joint venture partnerships and internal research programs. The company maintains additional information through its newsroom at https://nnw.fm/OTLC where stakeholders can access ongoing updates about the company's progress and research initiatives.